Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Georgetown University
Washington D.C., District of Columbia, United States
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
- University of Kansas Medical Center Research Institute, Inc.
Westwood, Kansas, United States
- Dana Farber- Partners Cancer Care, Inc
Boston, Massachusetts, United States
- Ichan School of Medicine at Mount Sinai
New York, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Huntsman Cancer Institute University of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Nov 2018
- Primary completion
- 6 Dec 2021
- Completion
- 7 Jun 2023
- Last update posted
- 3 Jul 2024
- Registered enrollment
- 26
- Registry id
- NCT03557918
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.